- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (33)
7 result(s) found for: PPA.
Displaying page 1 of 1.
EudraCT Number: 2008-005079-90 | Sponsor Protocol Number: PPA/904W/003 | Start Date*: 2008-12-18 | |||||||||||
Sponsor Name:Photopharmica Ltd | |||||||||||||
Full Title: Phase II randomised, placebo controlled trial to investigate repeat dose antimicrobial photodynamic therapy in patients with chronic leg ulcers | |||||||||||||
Medical condition: Chronic leg ulcers | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002731-28 | Sponsor Protocol Number: P12-01/BP1.4979 | Start Date*: 2013-03-01 | |||||||||||
Sponsor Name:Bioprojet | |||||||||||||
Full Title: Randomized placebo controlled trial assessing the efficacy and safety of BP1.4979 in smoking cessation | |||||||||||||
Medical condition: Smoking cessation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023852-10 | Sponsor Protocol Number: 18F-AV-45-020 | Start Date*: 2011-10-03 | |||||||||||
Sponsor Name:Avid Radiopharmaceuticals, Inc. | |||||||||||||
Full Title: 18F-AV-45 Amyloid PET Imaging in Primary Progressive Aphasia | |||||||||||||
Medical condition: Focal dementia syndromes - primary aphasia | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000138-20 | Sponsor Protocol Number: AL001-2 | Start Date*: 2019-11-18 | |||||||||||
Sponsor Name:Alector Inc. | |||||||||||||
Full Title: A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in Heterozygous Carriers of Granulin or C9ORF72 Mutations Causative of... | |||||||||||||
Medical condition: Frontotemporal Dementia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003159-12 | Sponsor Protocol Number: J4B-MC-OKAA | Start Date*: 2021-12-24 | |||||||||||
Sponsor Name:Prevail Therapeutics, a wholly-owned subsidiary of Eli Lilly and Company | |||||||||||||
Full Title: A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM) | |||||||||||||
Medical condition: Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) ES (Temporarily Halted) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004066-18 | Sponsor Protocol Number: AL001-3 | Start Date*: 2020-07-06 | |||||||||||
Sponsor Name:Alector Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk For or With Frontotemporal Dementia Due to Heterozygou... | |||||||||||||
Medical condition: Frontotemporal Dementia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) PT (Trial now transitioned) NL (Trial now transitioned) ES (Temporarily Halted) BE (Trial now transitioned) SE (Trial now transitioned) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005733-16 | Sponsor Protocol Number: DNLI-H-0001 | Start Date*: 2022-07-19 | |||||||||||
Sponsor Name:Denali Therapeutics Inc. | |||||||||||||
Full Title: A Phase 1/2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Single Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in ... | |||||||||||||
Medical condition: Frontotemporal Dementia (FTD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Temporarily Halted) PT (Trial now transitioned) CZ (Completed) FR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
